Persistent Headache After Normalization of CSF Pressure
Headache is the most common symptom of both idiopathic intracranial hypertension (IIH) and spontaneous intracranial hypotension (SIH), and in many patients it persists despite successful normalization of intracranial pressure. In IIH, more than half of patients continue to have headache after papilledema resolution and ICP normalization. In SIH, while most patients experience headache resolution with definitive leak treatment, a significant minority develop chronic headache despite radiographic resolution of their CSF leak. Understanding the mechanisms of persistent headache — particularly the role of central sensitization — is essential for appropriate management, which follows the principles of treating primary headache disorders rather than further escalating pressure-modifying interventions.
Bottom Line
- IIH: 57% of patients continue to have headache at 12 months despite ocular remission; headache phenotype most commonly resembles migraine (52% in the IIHTT)
- SIH: Most patients improve with definitive leak treatment; 25% still have severe headache-related disability at 12 months post-surgery
- Central sensitization: The leading hypothesis for persistent headache; trigeminovascular system activation becomes self-sustaining even after the original pressure stimulus resolves
- Pressure-lowering treatments do not treat headache: Acetazolamide, shunting, and venous sinus stenting typically do not improve headache after ICP has normalized
- Treatment: Follow primary headache disorder guidelines; erenumab is the first headache preventive studied in IIH (positive open-label results)
- Monitoring: Continue ophthalmologic surveillance even when headache is in remission — papilledema can recur independently
Persistent Headache in IIH
Prevalence and Headache Phenotype
- Headache affects 84% of IIH patients at diagnosis (even higher in some studies)
- The headache phenotype most commonly resembles migraine (52% in the IIHTT), followed by tension-type headache (22%) and probable migraine (16%)
- IIH patients are 6 times more likely to develop migraine than the general population
- Baseline prevalence of migraine in IIH is approximately double the general population rate
Response to Pressure-Normalizing Treatment
| Treatment | Headache Outcome |
|---|---|
| Acetazolamide (IIHTT) | No more impact on headache-related disability than placebo at 6 months; ~70% continued to have headache despite treatment |
| CSF diversion (VP/LP shunt) | Headache persisted in 79% at 24 months, 42% at 35 months, 48% at 36 months across different studies |
| Venous sinus stenting | 83.5% continued to have headache at 3 months despite significant papilledema improvement; 73% classified their headache as improved |
| Overall | >50% have persistent headache after ICP normalization regardless of the modality used |
Critical Distinction
- Persistent headache after ICP normalization does not indicate treatment failure for IIH
- IIH should be conceptualized as two separate conditions: an optic nerve disorder and a headache disorder
- Headache does not correlate with opening pressure, papilledema grade, or visual function at baseline
- Venous sinus stenting should not be offered primarily for headache management in patients who are in ocular remission
Persistent Headache in SIH
Prevalence and Headache Phenotype
- Headache is the most common symptom of SIH, present in 98.5% of patients
- The headache is typically orthostatic initially but may lose its positional quality over time
- Location: Usually bilateral (holocephalic, occipital, frontal, fronto-occipital, temporal)
- Quality: Described as tightening, pulling, or throbbing
- If photophobia, phonophobia, and throbbing are present, it can be misdiagnosed as migraine
Response to Definitive Treatment
- Most patients with SIH have long-term resolution of symptoms when the CSF leak is definitively treated
- After epidural blood patch: 64% have symptomatic improvement initially, but long-term success is only ~29% for some leak types
- After surgical repair: Substantial early improvement in headache-related disability, but 25% continued to have severe disability at 12 months
- After CSF-venous fistula embolization: Resolution of headache in 75%, improvement in 20%, no change in 5% at a mean of 15 months
Risk Factors for Persistent Headache After SIH Treatment
- Normal initial brain MRI (lack of compensatory mechanisms suggests a poorer treatment response)
- Longer duration of symptoms before treatment
- History of preexisting headache or migraine
- Female sex
Mechanism: Central Sensitization
The leading hypothesis for persistent headache in both IIH and SIH is central sensitization of the trigeminovascular system:
The Trigeminovascular System
- Pain-sensitive intracranial structures include the meninges, meningeal vessels, dural sinuses, proximal arteries of the circle of Willis, and the pia mater
- These structures are innervated by the first division of the trigeminal nerve (supratentorial) and upper cervical spinal nerve roots and fibers of CN VII, IX, and X (infratentorial)
- Convergence at the trigeminal nucleus caudalis in the brainstem forms the trigeminovascular system — the final common pathway for both primary and secondary headache
Sensitization Process
| Stage | Process | Clinical Correlate |
|---|---|---|
| 1. Initial pressure stimulus | Elevated ICP (IIH) or brain sagging/venous congestion (SIH) activates meningeal nociceptors | Pressure-dependent headache; responds to pressure normalization |
| 2. Peripheral sensitization | Sustained nociceptor activation lowers the threshold for firing; chemical mediators (CGRP, substance P) released | Headache becomes more easily triggered; Valsalva or positional provocation |
| 3. Central sensitization | Second-order neurons in the trigeminal nucleus caudalis become hyperexcitable; transmission enhanced even without peripheral input | Headache becomes pressure-independent; cutaneous allodynia develops |
| 4. Self-sustaining | Central sensitization becomes autonomous; the original pressure stimulus is no longer required to maintain pain | Persistent headache despite normalized ICP; resembles chronic migraine |
IIH-Specific Mechanisms
- Dural venous sinus congestion (from transverse sinus stenosis) exposes sinus walls to calcitonin gene-related peptide (CGRP), an obligatory neuropeptide in the migraine pathway
- Continuous CGRP activation at the dural sinuses may sensitize central migraine processing pathways
- Once central sensitization is established, routine intracranial pressure fluctuations can maintain the headache even after the primary pressure elevation has resolved
SIH-Specific Mechanisms
- Brain sagging, venous engorgement, and pachymeningeal enhancement cause mechanical traction on pain-sensitive dural structures
- These dural stimuli may activate the same trigeminovascular sensitization cascade as in IIH
- Longer pre-treatment symptom duration allows more time for central sensitization to develop, explaining why delayed treatment is a risk factor for persistent headache
Differential Diagnosis of Persistent Headache
| Diagnosis | Key Features | Evaluation |
|---|---|---|
| Recurrent CSF leak (SIH) | Return of positional headache; new or recurrent radiographic stigmata on brain MRI | Repeat brain MRI (compare with “asymptomatic” baseline); spine imaging if new leak suspected |
| Recurrent elevated ICP (IIH) | Recurrence of papilledema (may occur without headache reemergence) | Repeat ophthalmologic assessment; papilledema can recur silently |
| Rebound intracranial hypertension | After SIH treatment; headache worse supine; onset days after successful leak repair | Usually self-limited; may require temporary acetazolamide |
| Medication-overuse headache | ≥15 headache days/month with regular use of acute analgesics ≥10–15 days/month | Detailed medication history; wean offending analgesics |
| Shunt-related headache (“shuntalgia”) | Scalp allodynia along shunt tubing; stent-related headache (ipsilateral to stent) | Clinical correlation; consider shunt evaluation |
| Postural orthostatic tachycardia syndrome (POTS) | Orthostatic headache with tachycardia; may develop from prolonged bed rest during SIH treatment | Tilt-table testing; heart rate assessment on standing |
| Cervicogenic headache | Unilateral, triggered by neck movement; may develop from deconditioning | Clinical assessment; cervical spine evaluation |
| Obstructive sleep apnea | Morning headache, excessive daytime sleepiness; can worsen both IIH and headache | Sleep study; particularly if patient does not fit typical demographic |
Treatment of Persistent Headache
General Principles
- Once ICP has normalized and papilledema has resolved (IIH) or the CSF leak has been successfully treated (SIH), treat headache as a primary headache disorder based on its phenotype
- The migrainous phenotype is most common — apply evidence-based migraine prevention strategies
- Address modifiable risk factors for headache chronification: obesity, medication overuse, depression, sleep disorders, caffeine overconsumption
- Prevention should be offered early when headache frequency exceeds 6 days/month with impairment, or for any patient with ≥10 headache days/month
Preventive Treatments for IIH Headache
| Category | Medications | IIH-Specific Considerations |
|---|---|---|
| High-efficacy, suitable for IIH | Topiramate (25–200 mg/d) | Weight loss promoting; also reduces ICP; teratogenic — stop before conception; avoid combining with acetazolamide |
| OnabotulinumtoxinA (155 U SC q12 weeks) | Weight neutral; no drug interactions with diuretics; safe in pregnancy (limited data); no metallic implant concerns | |
| CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) | Weight neutral; high efficacy; no diuretic interactions; stop 5 months before conception; injectable formulations bypass GI concerns post-bariatric surgery | |
| Gepants (rimegepant, atogepant) | Weight neutral; oral; stop when planning conception; CYP3A4 interactions to consider | |
| Eptinezumab (100–300 mg IV q3 months) | Weight neutral; IV administration; stop 5 months before conception | |
| Probable-efficacy, suitable for IIH | Venlafaxine XR (150 mg/d) | Weight neutral; treats comorbid depression; preferred drug in pregnancy if needed |
| Use with caution in IIH | Propranolol (120–240 mg/d) | Preferred for headache in pregnancy; avoid with bradycardia, asthma, severe depression |
| Amitriptyline (10–200 mg/d) | Effective but causes weight gain; second-line in pregnancy | |
| Avoid in IIH | Valproate / divalproex | Weight gain; teratogenic; promotes polycystic ovarian syndrome |
| Gabapentin / pregabalin | Weight gain; limited efficacy evidence | |
| Verapamil | Low efficacy; avoid |
Erenumab in IIH Headache
First Headache-Focused Study in IIH
- Study design: Open-label prospective study of 55 patients with IIH in ocular remission and chronic headache
- Treatment: Erenumab 70 mg SC monthly for 12 months
- Results: Reduced monthly moderate-to-severe headache days by 11 and any-severity headache days by 13 at 12 months
- Effective in patients with no prior migraine history and in those with medication-overuse headache
- Supports the role of CGRP in generating headache associated with IIH
- All CGRP-targeting therapies (erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant) are attractive options due to weight neutrality and lack of diuretic interactions
Neuromodulation
- External trigeminal nerve stimulation, transcranial magnetic stimulation, noninvasive vagus nerve stimulation, and remote electrical neuromodulation are available
- Well tolerated and weight neutral
- Limited study in IIH specifically
- Caution: Not approved or studied in patients with metallic implants (shunts, stents) — check compatibility before recommending
Monitoring After Headache Remission
Ongoing Surveillance
- Papilledema can recur without headache reemergence — a subset of patients treated with erenumab for headache developed recurrent papilledema after weight gain despite maintaining headache remission
- Continue neuro-ophthalmologic examinations even when headaches are well controlled
- Counsel all patients about weight management and the potential for relapse with weight gain
- For SIH: Brain MRI at 1–3 months post-treatment and then clinically as needed; have a baseline “asymptomatic” MRI for comparison
- For SIH: CSF leaks can recur at the same or different site; return of positional headache should prompt re-evaluation
Prognosis
| Population | Headache Prognosis |
|---|---|
| IIH with migraine phenotype | Lower rates of headache improvement and headache freedom at 12 months compared with non-migraine phenotype |
| IIH with non-migraine phenotype | More likely to achieve headache freedom with pressure-normalizing treatment |
| IIH overall | About twice as many IIH patients are prescribed opiate analgesics compared with migraine-only patients (population-based data); opiate use is a risk factor for headache chronification |
| SIH with short symptom duration | Better headache outcomes with earlier treatment |
| SIH with normal initial brain MRI | Poorer headache-related prognosis; may lack compensatory mechanisms that aid recovery |
| SIH with preexisting migraine | Higher risk of persistent headache after successful leak treatment |
References
- Fermo O. Treatment of persistent headache after normalization of CSF pressure. Continuum (Minneap Minn). 2025;31(3):769-789.
- Mollan SP, Grech O, Sinclair AJ. Headache attributed to idiopathic intracranial hypertension and persistent post-idiopathic intracranial hypertension headache: a narrative review. Headache. 2021;61(6):808-816.
- Mollan SP, Hoffmann J, Paemeleire K, et al. European headache federation guideline on idiopathic intracranial hypertension. J Headache Pain. 2018;19(1):93.
- Yiangou A, Mitchell JL, Vijay V, et al. Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain. 2020;21(1):116.
- Puustinen T, Tervonen J, Avellan C, et al. Psychiatric disorders are a common prognostic marker for worse outcome in patients with idiopathic intracranial hypertension. Clin Neurol Neurosurg. 2019;186:105527.